Clermont-Ferrand
Clermont-Ferrand
Clermont-Ferrand, Auvergne-Rhône-Alpes, France12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT07007312 | |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Intermediate Risk Non-Muscle Invasive Bladder Cancer | Recruiting | Phase 3 | 2026-10-07 | NCT06510374 | |
| Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07166094 | |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Recruiting | Phase 3 | 2026-09-25 | NCT06545955 | |
| A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | Biochemically Recurrent Prostate Cancer | Active, not recruiting | Phase 3 | 2026-07-07 | NCT05794906 | |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | cancer, neoplasm | Active, not recruiting | Phase 3 | 2026-07-07 | NCT04464226 | |
| Lysosomal Acid Lipase (LAL) Deficiency Registry | Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, Wolman disease, cholesteryl ester storage disease, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease | Recruiting | Not stated | 2026-03-06 | NCT01633489 | |
| Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting | Advanced Parkinson Disease | Active, not recruiting | Not stated | 2026-02-27 | NCT06639620 | |
| An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Recruiting | Not stated | 2026-02-17 | NCT06764693 | |
| Avenir® Cemented Hip Stem - PMCF | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Femoral Fractures, Hip Dislocation, Congenital, Hip Injuries, Leg Injuries, Musculoskeletal Abnormalities, bone fracture, developmental dysplasia of the hip, femoral neck fracture, hip fracture, injury, musculoskeletal system disorder | Active, not recruiting | Not stated | 2025-11-25 | NCT03396224 | |
| Impact Study of the MSProgress Quality Approach Support Tool for Healthcare Centers Multiprofessionals (MSP) of the AUvergne-Rhône-Alpes Region Using a Mixed Method Evaluating the Evolution of Indicators Chosen by MSPs and Their Use in Multi-professional Teams | Evaluation of the Impact of the MSProgress Quality Approach Support Tool on the Evolution of the Indicators Chosen by the MSPs in Comparison With Standard Care | Active, not recruiting | Not stated | 2025-09-17 | NCT07179289 | |
| The ECOSTRESS Study: Influence of the Objective Structured Clinical Examination on Stress Among Medical Student | Heart Rate Variability; Medical Student; Stress | Recruiting | Not stated | 2023-11-18 | NCT06138457 |